• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

mSphere . Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model

tetano

Editor, Senior Moderator
mSphere


. 2022 Feb 2;e0088321.
doi: 10.1128/msphere.00883-21. Online ahead of print.
Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model


Kuan-Ting Liu[SUP] #[/SUP][SUP] 1 2 [/SUP], Yu-Nong Gong[SUP] #[/SUP][SUP] 1 3 [/SUP], Chung-Guei Huang[SUP] #[/SUP][SUP] 3 4 [/SUP], Peng-Nien Huang[SUP] #[/SUP][SUP] 1 5 [/SUP], Kar-Yee Yu[SUP] 1 2 [/SUP], Hou-Chen Lee[SUP] 1 6 [/SUP], Sun-Che Lee[SUP] 1 7 [/SUP], Huan-Jung Chiang[SUP] 1 [/SUP], Yu-An Kung[SUP] 1 [/SUP], Yueh-Te Lin[SUP] 1 2 3 [/SUP], Mei-Jen Hsiao[SUP] 3 [/SUP], Po-Wei Huang[SUP] 3 [/SUP], Sheng-Yu Huang[SUP] 1 2 [/SUP], Hsin-Tai Wu[SUP] 1 [/SUP], Chih-Ching Wu[SUP] 1 2 4 8 [/SUP], Rei-Lin Kuo[SUP] 1 2 4 9 [/SUP], Kuan-Fu Chen[SUP] 10 11 12 [/SUP], Chuan-Tien Hung[SUP] 13 [/SUP], Kasopefoluwa Y Oguntuyo[SUP] 13 [/SUP], Christian S Stevens[SUP] 13 [/SUP], Shreyas Kowdle[SUP] 13 [/SUP], Hsin-Ping Chiu[SUP] 13 [/SUP], Benhur Lee[SUP] 13 [/SUP], Guang-Wu Chen[SUP] 1 3 14 15 [/SUP], Shin-Ru Shih[SUP] 1 3 4 16 [/SUP]



Affiliations

Abstract

Considering the urgent demand for faster methods to quantify neutralizing antibody titers in patients with coronavirus (CoV) disease 2019 (COVID-19), developing an analytical model or method to replace the conventional virus neutralization test (NT) is essential. Moreover, a "COVID-19 immunity passport" is currently being proposed as a certification for people who travel internationally. Therefore, an enzyme-linked immunosorbent assay (ELISA) was designed to detect severe acute respiratory syndrome CoV 2 (SARS-CoV-2)-neutralizing antibodies in serum, which is based on the binding affinity of SARS-CoV-2 viral spike protein 1 (S1) and the viral spike protein receptor-binding domain (RBD) to antibodies. The RBD is considered the major binding region of neutralizing antibodies. Furthermore, S1 covers the RBD and several other regions, which are also important for neutralizing antibody binding. In this study, we assessed 144 clinical specimens, including those from patients with PCR-confirmed SARS-CoV-2 infections and healthy donors, using both the NT and ELISA. The ELISA results analyzed by spline regression and the two-variable generalized additive model precisely reflected the NT value, and the correlation between predicted and actual NT values was as high as 0.917. Therefore, our method serves as a surrogate to quantify neutralizing antibody titer. The analytic method and platform used in this study present a new perspective for serological testing of SARS-CoV-2 infection and have clinical potential to assess vaccine efficacy. IMPORTANCE Herein, we present a new approach for serological testing for SARS-CoV-2 antibodies using innovative laboratory methods that demonstrate a combination of biology and mathematics. The traditional virus neutralization test is the gold standard method; however, it is time-consuming and poses a risk to medical personnel. Thus, there is a demand for methods that rapidly quantify neutralizing antibody titers in patients with COVID-19 or examine vaccine efficacy at a biosafety level 2 containment facility. Therefore, we used a two-variable generalized additive model to analyze the results of the enzyme-linked immunosorbent assay and found the method to serve as a surrogate to quantify neutralizing antibody titers. This methodology has potential for clinical use in assessing vaccine efficacy.

Keywords: SARS-CoV-2; enzyme-linked immunosorbent assay; neutralizing antibody; receptor-binding domain; spike protein; two-variable generalized additive model.
 
Back
Top Bottom